Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Promoter methylation of MCAM (show MCAM Proteins), ERalpha (show ESR1 Proteins) and ERbeta (show ESR2 Proteins) have a potential to be utilized as biomarker for the early detection of prostate cancer (PC) as their sensitivity and specificity seem to be better than serum PSA (show PLAG1 Proteins).
Data suggest no influence of chronic periodontitis treatment on PSA (show PLAG1 Proteins) levels in asymptomatic men.
Circulating total PSA (show PLAG1 Proteins) levels were strongly associated to leukocyte telomere length in a national sample of men without prostate cancer.
I might also point out that whether a particular surgical procedure did more good than harm at that time was highly dependent on whether it was conducted with good sterile procedure. PSA (show PLAG1 Proteins) screening is a contemporary example of this historical lesson
Data show that forkhead box M1 (show FOXM1 Proteins) protein (FOXM1 (show FOXM1 Proteins)) directly binds to the FHK binding motifs in the prostate specific antigen (PSA) promoter/enhancer regions.
Study suggests that the prognostic value of PSA (show PLAG1 Proteins) declines in heavily treated patients receiving enzalutamide
novel urinary gene expression signature that may be the least invasive of available options by not requiring a digital rectal examination or phlebotomy as a reflex test in men for whom PSA (show PLAG1 Proteins) testing raises the suspicion of prostate cancer
For PSA (show PLAG1 Proteins) screening to be cost-effective, it needs to be used conservatively and ideally in combination with a conservative management approach for low-risk disease
Both the incidence of early-stage prostate cancer and rates of PSA (show PLAG1 Proteins) screening have declined and coincide with 2012 USPSTF recommendation to omit PSA (show PLAG1 Proteins) screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality.
Distinctive immunohistochemical expression of PAX8 (show PAX8 Proteins) and lack of prostate-specific antigen can help in distinguishing this benign entity from prostatic adenocarcinoma.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
, prostate specific antigen
, prostate-specific antigen
, plasma kallikrein B1
, kallikrein-related peptidase 3